Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
This article was originally published in The Pink Sheet Daily
U.S.-based Alexion Pharmaceuticals has orphan designation in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder.
You may also be interested in...
WASHINGTON - Japan is giving more weight to innovation when pricing new drugs
Alexion believes the challenge of identifying new patients with the "ultra-orphan" blood disorder paroxysmal nocturnal hemoglobinuria who are candidates for the company's biologic Soliris (eculizumab) will be helped by diagnostic technology recently in-licensed by the firm
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.